sharon sanders
Editor-in-Chief & President
[h=1]Guillain-Barr? Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study[/h] Van-Mai Cao-Lormeau, PhD?
, Alexandre Blake, MD?
, Sandrine Mons, MSc
, St?phane Last?re, PharmD
, Claudine Roche, MSc
, Jessica Vanhomwegen, PhD
, Timoth?e Dub, MPH
, Laure Baudouin, MD
, Anita Teissier
, Philippe Larre, MD
, Anne-Laure Vial, MSc
, Christophe Decam, MD
, Val?rie Choumet, PhD
, Susan K Halstead, PhD
, Prof Hugh J Willison, PhD
, Lucile Musset, PhD
, Jean-Claude Manuguerra, PhD
, Prof Philippe Despres, PhD
, Prof Emmanuel Fournier, PhD
, Henri-Pierre Mallet, MD
, Didier Musso, MD
, Prof Arnaud Fontanet, DrPH?
, Jean Neil, MD?
, Fr?d?ric Ghawch?, MD?
snip
In conclusion, this is the first study to document a large series of patients who developed a Guillain-Barr? syndrome following Zika virus infection, a virus that previously used to be considered as causing only mild disease. Most (88%) of the patients with Guillain-Barr? syndrome reported symptomatic Zika virus infection that preceded the occurrence of neurological symptoms by a median of 6 days. All patients with Guillain-Barr? syndrome were of the AMAN type, characterised by distal motor nerve involvement, the absence of typical patterns and levels of anti-glycolipid antibodies, and faster recovery than usually observed in typical Guillain-Barr? syndrome. Because Zika virus is spreading rapidly across the Americas, at risk countries need to be prepared to have adequate intensive care beds capacity to manage patients with Guillain-Barr? syndrome.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)00562-6/fulltext
, Alexandre Blake, MD?
, Sandrine Mons, MSc
, St?phane Last?re, PharmD
, Claudine Roche, MSc
, Jessica Vanhomwegen, PhD
, Timoth?e Dub, MPH
, Laure Baudouin, MD
, Anita Teissier
, Philippe Larre, MD
, Anne-Laure Vial, MSc
, Christophe Decam, MD
, Val?rie Choumet, PhD
, Susan K Halstead, PhD
, Prof Hugh J Willison, PhD
, Lucile Musset, PhD
, Jean-Claude Manuguerra, PhD
, Prof Philippe Despres, PhD
, Prof Emmanuel Fournier, PhD
, Henri-Pierre Mallet, MD
, Didier Musso, MD
, Prof Arnaud Fontanet, DrPH?
, Jean Neil, MD?
, Fr?d?ric Ghawch?, MD?
snip
In conclusion, this is the first study to document a large series of patients who developed a Guillain-Barr? syndrome following Zika virus infection, a virus that previously used to be considered as causing only mild disease. Most (88%) of the patients with Guillain-Barr? syndrome reported symptomatic Zika virus infection that preceded the occurrence of neurological symptoms by a median of 6 days. All patients with Guillain-Barr? syndrome were of the AMAN type, characterised by distal motor nerve involvement, the absence of typical patterns and levels of anti-glycolipid antibodies, and faster recovery than usually observed in typical Guillain-Barr? syndrome. Because Zika virus is spreading rapidly across the Americas, at risk countries need to be prepared to have adequate intensive care beds capacity to manage patients with Guillain-Barr? syndrome.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)00562-6/fulltext